Jujuboside A ameliorates tubulointerstitial fibrosis in diabetic mice through down-regulating the YY1/TGF-ß1 signaling pathway.

Diabetic nephropathy (DN) is one of the most common complications of diabetes mellitus, which is characterized in renal tubulointerstitial fibrosis (TIF). The current study was designed to investigate the protective effect of Jujuboside A (Ju A) on TIF in type 2 diabetes (T2DM) mice, and explore its underlying anti-fibrosis mechanism. A mouse T2DM model was established using high fat diet (HFD) feeding combined with intraperitoneal injection of streptozotocin (STZ). Then, diabetic mice were treated with Ju A (10, 20 and 40 mg·kg-1·d-1, i.g.) for 12 weeks. Results showed that administration of Ju A not only down-regulated fasting blood glucose (FBG) levels, but also improved hyperlipidemia and renal function in diabetic mice. Moreover, the reduced ECM accumulation was observed in the renal cortex of Ju A treated diabetic mice, while the TIF progression was also attenuated by Ju A through blocking the epithelial-to-mesenchymal transition (EMT) of renal tubular epithelial cells (RTECs). Further mechanism studies showed that Ju A treatment effectively down-regulated the protein expression and subsequent nuclear translocation of Yin Yang 1 (YY1) in the renal cortex of diabetic mice, and reduced the levels of transforming growth factor-ß1 (TGF-ß1) in the serum and renal cortex of Ju A treated mice. According to invitro studies, the up-regulated YY1/TGF-ß1 signaling pathway was restored by Ju A in high glucose (HG) cultured HK-2 cells. Taken together, these findings demonstrated that Ju A can ameliorate the TIF of DN through down-regulating the YY1/TGF-ß1 signaling pathway.

Correlation research between fear of disease progression and quality of life in patients with lung cancer.

BACKGROUND: Lung cancer has the highest incidence rate and mortality rate of all malignancies. In recent years, the therapeutic effect of lung cancer has been greatly improved, but the fear of disease progression still directly affects the quality of life (QOL) of patients. The aim of this study was to evaluate the factors affecting the progression of fear of disease and its impact on the quality of life in patients with lung cancer. METHODS: From December 2019 to February 2020, 102 patients with lung cancer in the Department of Thoracic Oncology of a top three hospital were investigated by using the simplified fear of disease progression scale (FoP-Q-SF) and the quality-of-life scale for cancer patients (FACT-G). Data were collected and statistically analyzed by SPSS25.0 software. RESULTS: A total of 110 questionnaires were distributed and 102 valid questionnaires were recovered, indicating a recovery rate of 92.7%. The results of multiple stepwise regression analyses showed that blood group, monthly income, and mood state were the influencing factors for the progression of phobic diseases in cancer patients (P<0.05), and the score of progression of phobic disease was negatively correlated with the quality-of-life score (r=-0.382). CONCLUSIONS: The progress of phobic diseases in patients with lung cancer seriously affects their QOL, and further attention by medical staff in providing health education, psychological counseling, social support, and other measures is required.